

CFO's Letter	20
Corporate Governance	22
Consolidated Financial Statements	28
Holding Company Statements	47
► Shareholder Information	52
Year 2002 Highlights	54

Shareholder Information

Share price

The following table shows the reported high and low quarterly closing share price of the Actelion shares on the SWX New Market during the year 2002.

	High	Low
First Quarter	80.00	62.25
Second Quarter	80.25	54.00
Third Quarter	57.00	41.50
Fourth Quarter	66.05	43.65

On 31 December 2002, the last reported closing share price was CHF 61 and market capitalization of Actelion Ltd was CHF 1.29 billion, compared with a share price of CHF 78 and market capitalization of CHF 1.6 billion the previous year. The total number of shareholders on 31 December 2002 was 4731.

Listing

Actelion Ltd is organized under Swiss law and is the holding company of the Actelion Group. The company's initial equity funding was provided in 1998 and 1999 in two separate rounds of financing totaling CHF 66 million.

The registered shares of Actelion Ltd have been listed on the SWX New Market since April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company's Initial Public Offering at the price of CHF 260 per share raising CHF 246.6 million. On June 20, 2001, Actelion Ltd announced a 4:1 split in its shares.

On September 9, 2002 Actelion listed the company's registered shares on the SWX Main Market. The trading symbol remains the same and the company will continue to report full quarterly figures.

Investor Relations

Calendar 2003

March 4	Media/Analyst Conference
April 23	Annual General Meeting of Shareholders
May 6	Q1 Results
August 5	Q2 Results
November 4	Q3 Results

Board of Directors

Werner Henrich

Senior Vice President, F. Hoffmann-La Roche
(Pharmaceuticals Division)

Rudolf Maag

Former CEO, Synthes-Stratec, Inc.

Fred J. Meyer

Retired Vice Chairman, Omnicom Group

André J. Mueller

Senior Vice President

Joël Besse

Senior Principal, Atlas Venture

Jane Royston

Branco Weiss Professor of Entrepreneurship
& Innovation, Swiss Federal Institute
of Technology, Lausanne

Jean-Paul Clozel

Founder, Chief Executive Officer

Robert E. Cawthorn Chairman

Retired Chairman and CEO, Rhône-Poulenc-
Rorer

Thomas Widmann Vice-Chairman

Founder

Scientific Advisory Board

Joël Ménard

Professor of Public Health, University Pierre
et Marie Curie, Paris

Donald Hilvert

Professor of Chemistry at the Swiss Federal
Institute of Technology (ETH), Zürich

Richard Tsien

Professor of the Department of Molecular
and Cellular Physiology, Stanford University,
Palo Alto

Craig Pratt

Professor of Medicine and Cardiology, Baylor
College of Medicine, Houston

Business Executive Board

Jean-Paul Clozel

Founder, Chief Executive Officer

Simon Buckingham

President, Head of US, Canada, Asia Pacific

Isaac Kobrin

Senior Vice President, Head of Clinical
Development

André J. Mueller

Senior Vice President, Chief Financial Officer

Christian Chavy

President, Head of Europe, Middle East,
Latin America

Louis de Lassence

Vice President, Head of Corporate Services

Satoshi Tanaka

President and Representative Director, Japan

Senior Management

Frédéric Bodin

Senior Vice President, Head of International
Medical Marketing

Martine Clozel

Senior Vice President, Head of Drug Discov-
ery Pharmacology & Preclinical Development

Walter Fischli

Founder, Senior Vice President, Head of Drug
Discovery Molecular Biology & Biochemistry